Compare CBNK & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBNK | RZLT |
|---|---|---|
| Founded | 1974 | 2010 |
| Country | United States | United States |
| Employees | N/A | 58 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.3M | 471.0M |
| IPO Year | 2018 | 2011 |
| Metric | CBNK | RZLT |
|---|---|---|
| Price | $38.71 | $4.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $43.56 | $9.80 |
| AVG Volume (30 Days) | 133.0K | ★ 1.7M |
| Earning Date | 10-26-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | ★ 60.85 | 23.47 |
| EPS | ★ 1.60 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.44 | N/A |
| Revenue Next Year | $10.21 | $2,481.32 |
| P/E Ratio | $24.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.40 | $1.07 |
| 52 Week High | $40.70 | $11.46 |
| Indicator | CBNK | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 57.58 | 58.48 |
| Support Level | $35.70 | $4.36 |
| Resistance Level | $40.70 | $4.71 |
| Average True Range (ATR) | 0.75 | 0.32 |
| MACD | 0.08 | 0.10 |
| Stochastic Oscillator | 61.20 | 77.39 |
Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage. The company generates majority revenue from the Commercial bank sector. Commercial Banking division focuses on providing personalized service to commercial clients throughout the operations supplemented by lending outside primary market as well as engaging in government guaranteed lending on a national basis.
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.